Spread the love

A recent study reveals that the use of certain anti-inflammatories has reduced the number of deaths from Covid-19.

A study conducted by the University of Washington and published in the journal JAMA reveals that certain anti-inflammatories had made it possible to limit the number of deaths due to Covid-19. The clinical trial, dubbed ACTIV-1 Immune Modulator, was conducted on nearly 2,000 people in the United States and Latin America.

On the same subject

In 2020, Covid 19 rose to the rank of 3rd cause of death in France

Three anti-inflammatories, infliximab, abatacept or cenicriviroc, have been tested in hospitalized Covid patients, in addition to standard care based on corticosteroids (dexamethasone) and an antiviral (remdevisir). Doctors wanted to know if they could curb the inflammatory process caused by the virus.

Reduced mortality rate

By comparing with patients who had received only standard care, they found that those who had taken the anti-inflammatories were less likely to die. Two of the drugs had an interesting role: infliximab and abatacept, on mortality. Cenicriviroc, on the other hand, has not been proven.

For those who received abtacept, the death rate was 11%, compared to 15.1% in the placebo group. And for those who received infliximab, the death rate was 10.1% compared to 14.5% in the placebo group. On the other hand, the researchers note that the recovery time of patients affected by Covid-19 was not improved by taking these treatments.

Source: JAMA

Leave a Reply

Your email address will not be published.